This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders

by | Aug 8, 2026